These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36564103)

  • 1. Improving use of proton pump inhibitors with dual antiplatelet therapy in patients admitted with acute coronary syndrome.
    Jinadu T; Radhakrishnan A; Fan L
    BMJ Open Qual; 2022 Dec; 11(4):. PubMed ID: 36564103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitor co-prescription with dual antiplatelet therapy among patients with acute coronary syndrome in Qatar.
    Awaisu A; Hamou F; Mekideche L; El Muabby N; Mahfouz A; Mohammed S; Saad A
    Int J Clin Pharm; 2016 Apr; 38(2):353-61. PubMed ID: 26749343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton Pump Inhibitors and In-Hospital Gastrointestinal Bleeding in Patients With Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy.
    Zhou M; Zhang J; Liu J; Smith SC; Ma C; Ge J; Huo Y; Fonarow GC; Liu J; Hao Y; Gao F; Sun Y; Morgan L; Yang N; Hu G; Zeng Y; Han Y; Zhao D;
    Mayo Clin Proc; 2022 Apr; 97(4):682-692. PubMed ID: 35164933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guideline versus clinician recommended duration of dual antiplatelet therapy following acute coronary syndrome (ANZACS-QI 78).
    Rees SJ; Kerr AJ
    N Z Med J; 2024 May; 137(1595):64-72. PubMed ID: 38754114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Meta-analysis on safety and efficacy of dual antiplatelet therapy combining with proton pump inhibitors for patients after percutaneous coronary intervention].
    Che QQ; Wu Q; Liang YB; Sun RM; Lyu QW; Ma JL; Hu H; Lin X; Xu GL; Sun SG; Zhang C; Wang QY; Yu J; Bai F
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Feb; 47(2):129-140. PubMed ID: 30818941
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.
    Vaduganathan M; Cannon CP; Cryer BL; Liu Y; Hsieh WH; Doros G; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Bhatt DL;
    Am J Med; 2016 Sep; 129(9):1002-5. PubMed ID: 27143321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.
    Tsai YW; Wen YW; Huang WF; Chen PF; Kuo KN; Hsiao FY
    J Gastroenterol; 2011 Jan; 46(1):39-45. PubMed ID: 20811753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.
    Hoedemaker NPG; Damman P; Ottervanger JP; Dambrink JHE; Gosselink ATM; Kedhi E; Kolkman E; de Winter RJ; van 't Hof AWJ
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):127-138. PubMed ID: 30084902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction.
    Sehested TSG; Carlson N; Hansen PW; Gerds TA; Charlot MG; Torp-Pedersen C; Køber L; Gislason GH; Hlatky MA; Fosbøl EL
    Eur Heart J; 2019 Jun; 40(24):1963-1970. PubMed ID: 30851041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis.
    Khan MY; Siddiqui WJ; Alvarez C; Aggarwal S; Hasni SF; Ahmad A; Eisen H
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):847-853. PubMed ID: 29596078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Provision of gastroprotective medication and bleeding risk following acute coronary syndrome.
    Badar A; Scaife J; Yan AT; Robinson SD; Zaman AG; Purcell IF; Ahmed JM; Egred M; Edwards RJ; Spyridopoulos I; Keavney BD; Bagnall AJ
    J Invasive Cardiol; 2013 Aug; 25(8):397-401. PubMed ID: 23913604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitor in the prevention of upper gastrointestinal mucosal injury associated with dual antiplatelet therapy after coronary artery bypass grafting (DACAB-GI-2): study protocol for a randomized controlled trial.
    Zhu Y; Wang X; Yang Y; Liu L; Zhao Q; Yu L
    Trials; 2022 Jul; 23(1):569. PubMed ID: 35840999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-Analysis of Efficacy and Safety of Proton Pump Inhibitors with Dual Antiplatelet Therapy for Coronary Artery Disease.
    Khan SU; Lone AN; Asad ZUA; Rahman H; Khan MS; Saleem MA; Arshad A; Nawaz N; Sattur S; Kaluski E
    Cardiovasc Revasc Med; 2019 Dec; 20(12):1125-1133. PubMed ID: 30773427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy.
    Casado Arroyo R; Polo-Tomas M; Roncalés MP; Scheiman J; Lanas A
    Heart; 2012 May; 98(9):718-23. PubMed ID: 22523056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed.
    Schreiner GC; Laine L; Murphy SA; Cannon CP
    Crit Pathw Cardiol; 2007 Dec; 6(4):169-72. PubMed ID: 18091407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial: the impact of gastrointestinal risk factor screening and prophylactic proton pump inhibitor therapy in patients receiving dual antiplatelet therapy.
    Jensen BES; Hansen JM; Larsen KS; Junker AB; Lassen JF; Jensen SE; Schaffalitzky de Muckadell OB
    Eur J Gastroenterol Hepatol; 2017 Oct; 29(10):1118-1125. PubMed ID: 28678044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study.
    Ortolani P; Marino M; Marzocchi A; De Palma R; Branzi A
    J Cardiovasc Med (Hagerstown); 2012 Dec; 13(12):783-9. PubMed ID: 21252697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
    Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant use of proton pump inhibitors and dual antiplatelet therapy for cardiovascular outcomes.
    Mandurino-Mirizzi A; Leonardi S; Melloni C
    Minerva Endocrinol; 2017 Sep; 42(3):228-237. PubMed ID: 27808485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.